Status:

COMPLETED

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

Lead Sponsor:

Elliott Vichinsky

Conditions:

Thalassemia

Iron Overload

Eligibility:

All Genders

8+ years

Phase:

PHASE2

Brief Summary

This is a pilot study looking at the safety and efficacy of giving combination chelation with deferasirox and deferoxamine. The hypothesis is that combination chelation is safe in decreasing overall i...

Detailed Description

This was a phase two pilot clinical trial designed to evaluate the safety and efficacy of the combination of deferasirox and deferoxamine in transfusion dependent thalassemia with a range of systemic ...

Eligibility Criteria

Inclusion

  • Transfusion Dependent Thalassemia
  • If iron between 5-15 mg/g dry liver by SQUID, subject must have a documented endocrinopathy or cardiac finding
  • Older than 8 years

Exclusion

  • Participating on another interventional clinical trial

Key Trial Info

Start Date :

September 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2012

Estimated Enrollment :

22 Patients enrolled

Trial Details

Trial ID

NCT00901199

Start Date

September 1 2007

End Date

October 1 2012

Last Update

August 12 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

CHRCO

Oakland, California, United States, 94609

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload | DecenTrialz